Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Expert Opin Investig Drugs ; 19(4): 489-512, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20367191

ABSTRACT

IMPORTANCE OF THE FIELD: PPARgamma full agonists (pioglitazone and rosiglitazone) are the mainstay drugs for the treatment of type 2 diabetes; however, mechanism-based side effects have limited their full therapeutic potential. In recent years, much progress has been achieved in the discovery and development of selective PPARgamma modulators (SPPARgammaMs) as safer alternatives to PPARgamma full agonists. AREAS COVERED IN THIS REVIEW: This review focuses on the preclinical and clinical data of all the SPPARgammaMs discovered so far, retrieved by searching PubMed, Prous Integrity database and company news updates from 1999 to date. WHAT THE READER WILL GAIN: Here we thoroughly discuss SPPARgammaMs' mode of action, briefly examine new ways to identify superior SPPARgammaMs, and finally, compare and contrast the pharmacological and safety profile of various agents. TAKE HOME MESSAGE: The preclinical and clinical findings clearly suggest that selective PPARgamma modulators have the potential to become the next generation of PPARgamma agonists: effective insulin sensitizers with a superior safety profile to that of PPARgamma full agonists.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Drug Discovery/trends , Hypoglycemic Agents/therapeutic use , PPAR gamma/agonists , PPAR gamma/physiology , Adipocytes/drug effects , Adipocytes/metabolism , Animals , Drug Discovery/methods , Humans , Hypoglycemic Agents/adverse effects , Insulin Resistance/genetics , Insulin Resistance/physiology , Organ Specificity/genetics , Organ Specificity/physiology , PPAR gamma/biosynthesis , PPAR gamma/genetics
2.
J Neurosci Res ; 87(6): 1400-11, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19115407

ABSTRACT

Global ischemia was induced in gerbil by bilateral occlusion of the common carotid arteries for 5 min. Sodium ionophore monensin or sodium channel blocker tetrodotoxin (TTX) was administered at doses of 10 micorg/kg, i.p., 30 min before ischemia induction; the dose was repeated after 22 hr. Subsequently, brain infarct occurred, determined at 24 hr after occlusion. Large, well-demarcated infarcts were observed in both hemispheres, an important observation because it critically influences the interpretation of the data. Because nitric oxide (NO) production is thought to be related to ischemic neuronal damage, we examined increases in Ca(2+) influx, which lead to the activation of nitric oxide synthase (NOS). Then we evaluated the contributions of neuronal NOS, endothelial NOS, and inducible NOS to NO production in brain cryosections. The cytosolic release of apoptogenic molecules like cytochrome c and p53 were confirmed after 24 hr of reflow. TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) labeling detected the apoptotic cells, which were confirmed in neuron-rich cell populations. After 24 hr, all the ischemic changes were amplified by monensin and significantly attenuated by TTX treatment. Additionally, the nesting behavior and histological outcomes were examined after 7 day of reflow. The neuronal damage in the hippocampal area and significant decrease in nesting scores were observed with monensin treatment and reduced by TTX pretreatment after day 7 of reflow. To our knowledge, this report is the first to highlight the involvement of the voltage-sensitive Na(+) channel in possibly regulating in part NO system and apoptosis in a cytochrome c-dependent manner in global ischemia in the gerbil, and thus warrants further investigation.


Subject(s)
Apoptosis , Brain Ischemia/pathology , Brain/pathology , Monensin/pharmacology , Neurons/physiology , Sodium Channels/metabolism , Tetrodotoxin/pharmacology , Animals , Brain/metabolism , Brain Ischemia/metabolism , Calcium/metabolism , Cytochromes c/metabolism , DNA Fragmentation , Endothelial Cells/physiology , Gerbillinae , Hippocampus/pathology , Hippocampus/physiopathology , In Situ Nick-End Labeling , Ionophores/pharmacology , Male , Nitric Oxide Synthase/metabolism , Sodium Channel Blockers/administration & dosage , Tumor Suppressor Protein p53/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...